Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + vinflunine
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Epirubicin + vinflunine is a combination chemotherapy regimen used primarily as a first-line treatment in metastatic breast cancer. Epirubicin is an anthracycline antineoplastic agent that intercalates into DNA, inhibits topoisomerase II, and interferes with DNA replication and transcription, leading to cytotoxicity. Vinflunine is a vinca alkaloid derivative that disrupts microtubule dynamics, inhibiting mitosis and inducing apoptosis in cancer cells. The combination aims to enhance antitumor efficacy by targeting different mechanisms of cell division and survival pathways. Clinical studies have evaluated this combination for safety, pharmacokinetics, and therapeutic activity in metastatic breast cancer patients[1][4][3].
- Other names
- epirubicin + vinflunine
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on epirubicin + vinflunine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + vinflunine.